Antibodies that bind to repulsive guidance molecule A (RGMA)

Patent metadata

Field	Value
Publication number	US-9365643-B2
Application number	US-201414580818-A
Country	US
Kind code	B2
Filing date	Dec 23, 2014
Priority date	Jan 27, 2012
Publication date	Jun 14, 2016
Grant date	Jun 14, 2016

Abstract

Provided herein are antibodies that bind to Repulsive Guidance Molecule a (RGMa) and methods of using the antibodies to treat and diagnose neurite degenerative diseases and disorders.

First claim

We claim:

1. An isolated antibody, the antibody comprising:
(a) a variable heavy domain comprising a complementarity-determining region (CDR) 1 comprising an amino acid sequence as set forth in SEQ ID NO:2, a CDR2 comprising an amino acid sequence as set forth in SEQ ID NO:3, and a CDR3 comprising an amino acid sequence as set forth in SEQ ID NO:4, and a variable light domain comprising a CDR1 comprising an amino acid sequence as set forth in SEQ ID NO:6, a CDR2 comprising an amino acid sequence as set forth in SEQ ID NO:7, and a CDR3 comprising an amino acid sequence as set forth in SEQ ID NO:73; or
(b) a light chain variable amino acid sequence as set forth in SEQ ID NO:146 and a heavy chain variable amino acid sequence as set forth in SEQ ID NO:147

wherein the antibody binds to Repulsive Guidance Molecule a (RGMa).

2. The isolated antibody of claim 1 , wherein the antibody is selected from the group consisting of a human antibody, an immunoglobulin molecule, a disulfide linked Fv, a monoclonal antibody, an affinity matured, a scFv, a chimeric antibody, a CDR-grafted antibody, a diabody, a humanized antibody, a multispecific antibody, a Fab, a dual specific antibody, a DVD, a Fab′, a bispecific antibody, a F(ab′)2, and a Fv.

3. The isolated antibody of claim 2 , wherein the antibody is a human antibody.

4. The isolated antibody of claim 2 , wherein the antibody is a monoclonal antibody.

5. The isolated antibody of claim 2 , wherein the antibody is an affinity matured antibody.

6. The isolated antibody of claim 2 , wherein the antibody is a chimeric antibody.

7. The isolated antibody of claim 2 , wherein the antibody is a humanized antibody.

8. The isolated antibody of claim 2 , wherein the antibody is a Fab, a Fab′, a F(ab′)2 or Fv.

9. The isolated antibody of claim 2 , wherein the antibody is a dual specific antibody, a DVD or a bispecific antibody.

10. The isolated antibody of claim 1 , further comprising a constant sequence of SEQ ID NO:143.

11. The isolated antibody of claim 1 , wherein the antibody comprises a light chain variable amino acid sequence as set forth in SEQ ID NO:146 and a heavy chain variable amino acid sequence as set forth in SEQ ID NO:147.

12. A pharmaceutical composition comprising the antibody of claim 1 .

13. A pharmaceutical composition comprising the antibody of claim 7 .

Assignees

• Abbvie Deutschland
• Abbvie Inc

Inventors

• Mueller Bernhard
• Huang Lili
• Bardwell Philip D
• Kutskova Yuliya
• Memmott John

Classifications

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P27/02

  Ophthalmic agents · CPC title

• A61P27/06

  Antiglaucoma agents or miotics · CPC title

• A61P3/02

  Nutrients, e.g. vitamins, minerals · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title